Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.28
0.00 (0.00%)
Jul 2, 2026, 4:00 PM EDT - Market closed
Emergent BioSolutions Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -8.6 | 52.6 | -190.6 | -760.5 | -211.6 | 219.5 |
Depreciation & Amortization | 103.2 | 105.6 | 116.2 | 146.4 | 147.4 | 127.9 |
Stock-Based Compensation | 16.6 | 16.2 | 18 | 23.1 | 45.1 | 42.4 |
Other Adjustments | -20.2 | 18.6 | 26.4 | 455 | -12.9 | 75.4 |
Change in Receivables | 59.9 | 25.5 | -24.4 | -21.6 | 118.1 | -16.2 |
Changes in Inventories | -12.3 | -30.3 | -24.5 | 0.6 | -57.1 | -66.6 |
Changes in Accounts Payable | -17.4 | -8.4 | -33 | 10.6 | -14 | -1.6 |
Changes in Accrued Expenses | -7.4 | -24.4 | -2.3 | -61.3 | -67.5 | -5.2 |
Changes in Income Taxes Payable | 11.3 | -1.7 | 23.3 | -16.2 | 28.7 | -31.3 |
Changes in Unearned Revenue | 8.7 | 5.2 | -20.3 | 5.9 | 9.6 | -31.8 |
Changes in Other Operating Activities | 1.7 | 11.7 | 169.9 | 11.7 | -19.9 | 7.7 |
Operating Cash Flow | 148 | 170.6 | 58.7 | -206.3 | -34.1 | 320.2 |
Operating Cash Flow Growth | 34.42% | 190.63% | - | - | - | -40.36% |
Capital Expenditures | -12.6 | -13.8 | -22.9 | -51.6 | -115.8 | -224.1 |
Purchases of Investments | - | -5 | - | - | - | - |
Payments for Business Acquisitions | - | - | - | - | -243.7 | - |
Proceeds from Business Divestments | 0.1 | 38.2 | 118.1 | 270.2 | - | - |
Other Investing Activities | 20 | 50 | 30 | -6.3 | -21.8 | - |
Investing Cash Flow | 7.5 | 69.4 | 125.2 | 212.3 | -381.3 | -224.1 |
Short-Term Debt Issued | - | - | 65 | 20 | 598 | - |
Short-Term Debt Repaid | - | - | -284.2 | -398.8 | - | - |
Net Short-Term Debt Issued (Repaid) | - | - | -219.2 | -378.8 | 598 | - |
Long-Term Debt Issued | - | - | 219 | - | - | - |
Long-Term Debt Repaid | - | -108.7 | -198.2 | -164.6 | -33.8 | -35.9 |
Net Long-Term Debt Issued (Repaid) | - | -108.7 | 20.8 | -164.6 | -33.8 | -35.9 |
Issuance of Common Stock | -0.1 | 2.2 | 10.8 | 10.2 | 5 | 15.9 |
Repurchase of Common Stock | -33.9 | -24.9 | - | - | -82.1 | -106 |
Net Common Stock Issued (Repurchased) | -34 | -22.7 | 10.8 | 10.2 | -77.1 | -90.1 |
Other Financing Activities | -3.7 | -5.2 | -2.4 | -2.5 | -5.9 | -15 |
Financing Cash Flow | -147.6 | -136.6 | -190 | -535.7 | 481.2 | -141 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | 0.8 | 0.1 | -1.2 | -1.2 | 0.5 | -0.3 |
Net Cash Flow | 8.7 | 103.5 | -6.1 | -530.9 | 66.3 | -45.2 |
Free Cash Flow | 135.4 | 156.8 | 35.8 | -257.9 | -149.9 | 96.1 |
Free Cash Flow Growth | -13.65% | 337.99% | - | - | - | -75.67% |
FCF Margin | 20.01% | 21.11% | 3.43% | -24.58% | -13.41% | 5.42% |
Free Cash Flow Per Share | 2.47 | 2.77 | 0.68 | -5.04 | -2.99 | 1.78 |
Levered Free Cash Flow | 66.6 | -12.2 | -182.6 | -1,258 | 264 | -41.4 |
Unlevered Free Cash Flow | 135.9 | 107.49 | 61.42 | -709.41 | -252.86 | 22.15 |